Technology, injections & supplies

Omnipod 5’s updated algorithm and a tighter target option

Insulet rolled out an enhanced Omnipod 5 algorithm in the US, with a new lower glucose-target option and added FreeStyle Libre 3 Plus compatibility.

Written by Updated 4 June 2026 4 min read
(1) Say, "O disbelievers, (2) I do not worship what you worship. (3) Nor are you worshippers of what I worship. (4) Nor will I be a worshipper of what you worship. (5) Nor will you be worshippers of what I worship. (6) For you is your religion, and for me is my religion." (Quran_Al-Kāfirūn).
Photo by Peaky Frames on Unsplash
The 60-second answer

Insulet has updated the software that runs the Omnipod 5, its tubeless patch pump, in the United States. Two things changed: the automation was improved, and there is now an option to aim for a lower glucose target than before, down to about 5.6 mmol/L. It also works with another sensor there, the FreeStyle Libre 3 Plus. A glucose target is the level the system steers toward, and choosing one is a clinical decision, so it is set with your team rather than dialled in on a hunch. UK updates arrive on their own timeline, separate from the US, so nothing about your pump changes today.

  • The Omnipod 5 is a tubeless patch pump that runs a closed loop, adjusting your background insulin automatically from a glucose sensor.
  • The update adds a lower target option (down to 100 mg/dL in US units, roughly 5.6 mmol/L), so the system can aim for a tighter level.
  • A glucose target is the number the automation steers toward: it is a setting chosen with your team, not a dose you work out yourself.
  • A lower target can mean more time in range for some people, but it can also raise the chance of lows, which is exactly why it is an individual decision.
  • This is a US rollout: UK algorithm updates and sensor options follow separately, so check with your team about what is available here.
What was announced

What the update actually adds

Insulet said it is rolling out an enhanced Omnipod 5 algorithm in the US, along with two practical changes. The first is a new, lower glucose-target option, taking the choice down to 100 mg/dL, which is roughly 5.6 mmol/L in the units used in the UK. The second is compatibility with Abbott’s FreeStyle Libre 3 Plus sensor, giving US users another sensor to pair with the pump. Together they point in a clear direction: tighter, more customisable targets and more sensor choice.

Why it matters here

Why a lower target is a decision, not a default

Aiming for a lower target sounds straightforwardly good, and for some people it does mean more time in range, the share of the day your glucose spends in the band you and your team have agreed. But a lower target is not automatically the right choice for everyone. Steering toward a tighter number brings glucose closer to the point where lows happen, so the benefit has to be weighed against your own risk of hypos, how well you feel a low coming on, and the shape of your day. That balance is different from person to person, which is the whole reason a target is set with a clinician rather than picked off a spec sheet.

For UK readers the immediate takeaway is modest. This is a US rollout, and UK updates to the Omnipod 5, including which targets and sensors are available, follow on their own timeline. If you use an Omnipod 5 here, nothing changes today, and the useful move is not to try to chase a tighter target yourself but to ask your team what the right target is for you and what your system currently supports.

What to notice

Worth knowing

A glucose target is a setting the loop steers toward, and it is chosen with your diabetes team, not adjusted on your own to chase a number.
A lower, tighter target can mean more time in range for some people, but it can raise the risk of lows, so it is an individual trade-off.
This update is a US rollout: UK Omnipod 5 algorithm and sensor changes follow separately, so what is available to you may differ.
If you feel your current target is not right for you, that is a conversation for your next appointment rather than a self-service change.
What to ask your team

Questions that make an appointment useful

"What glucose target is right for me on my system, and would a lower one suit me or raise my risk of lows?"
"When are UK Omnipod 5 updates like this expected, and would they change anything for me?"
"How do we tell whether my current target is working well for my time in range and my lows?"
"If a tighter target became available to me, how would we trial it safely?"
Sources